David A. Siegel Ventyx Biosciences, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 172,400 shares of VTYX stock, worth $608,572. This represents 0.0% of its overall portfolio holdings.

Number of Shares

172,400

Previous 196,529 12.28%

Holding current value

$608,572

Previous $226,000 62.83%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$0.84 - $2.65 $20,268 - $63,941	-24,129 Reduced 12.28%	172,400 $368,000
Q1 2025 May 15, 2025	SELL	$1.15 - $2.52 $694,911 - $1.52 Million	-604,271 Reduced 75.46%	196,529 $226,000
Q4 2024 Feb 14, 2025	BUY	$1.72 - $3.12 $576,888 - $1.05 Million	335,400 Added 72.07%	800,800 $1.75 Million
Q3 2024 Nov 14, 2024	BUY	$1.85 - $3.2 $466,940 - $807,680	252,400 Added 118.5%	465,400 $1.01 Million
Q2 2024 Aug 14, 2024	BUY	$2.31 - $5.59 $287,826 - $696,514	124,600 Added 140.95%	213,000 $492,000
Q1 2024 May 15, 2024	SELL	$1.9 - $10.13 $1.94 Million - $10.3 Million	-1,020,700 Reduced 92.03%	88,400 $486,000
Q4 2023 Feb 14, 2024	BUY	$2.08 - $31.18 $2.31 Million - $34.6 Million	1,109,100 New	1,109,100 $2.74 Million
Q2 2023 Aug 14, 2023	BUY	$28.53 - $39.55 $233,946 - $324,310	8,200 New	8,200 $268,000
Q4 2022 Feb 14, 2023	BUY	$24.16 - $36.38 $531,520 - $800,360	22,000 Added 275.0%	30,000 $983,000
Q3 2022 Nov 14, 2022	BUY	$12.64 - $38.7 $101,120 - $309,600	8,000 New	8,000 $279,000

Others Institutions Holding VTYX

# of Institutions

122

Shares Held

49.4M

Call Options Held

70.4K

Put Options Held

51.4K

View Full List

About Ventyx Biosciences, Inc.

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $200M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

More about VTYX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account